JP2021535152A5 - - Google Patents

Info

Publication number
JP2021535152A5
JP2021535152A5 JP2021510846A JP2021510846A JP2021535152A5 JP 2021535152 A5 JP2021535152 A5 JP 2021535152A5 JP 2021510846 A JP2021510846 A JP 2021510846A JP 2021510846 A JP2021510846 A JP 2021510846A JP 2021535152 A5 JP2021535152 A5 JP 2021535152A5
Authority
JP
Japan
Prior art keywords
disease
ripk2
composition according
pharmaceutical composition
inhibitor
Prior art date
Application number
JP2021510846A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020047414A5 (https=
JP2021535152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049071 external-priority patent/WO2020047414A1/en
Publication of JP2021535152A publication Critical patent/JP2021535152A/ja
Publication of JP2021535152A5 publication Critical patent/JP2021535152A5/ja
Publication of JPWO2020047414A5 publication Critical patent/JPWO2020047414A5/ja
Pending legal-status Critical Current

Links

JP2021510846A 2018-08-31 2019-08-30 神経変性障害を処置するためのｒｉｐキナーゼの阻害法 Pending JP2021535152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725647P 2018-08-31 2018-08-31
US62/725,647 2018-08-31
PCT/US2019/049071 WO2020047414A1 (en) 2018-08-31 2019-08-30 Inhibition of rip kinases for treating neurodegenerative disorders

Publications (3)

Publication Number Publication Date
JP2021535152A JP2021535152A (ja) 2021-12-16
JP2021535152A5 true JP2021535152A5 (https=) 2022-09-02
JPWO2020047414A5 JPWO2020047414A5 (https=) 2022-09-02

Family

ID=69643080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510846A Pending JP2021535152A (ja) 2018-08-31 2019-08-30 神経変性障害を処置するためのｒｉｐキナーゼの阻害法

Country Status (8)

Country Link
US (2) US20210322427A1 (https=)
EP (1) EP3843773A4 (https=)
JP (1) JP2021535152A (https=)
KR (1) KR20210053303A (https=)
CN (1) CN112638405A (https=)
AU (1) AU2019328532A1 (https=)
CA (1) CA3109364A1 (https=)
WO (1) WO2020047414A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022072694A1 (en) * 2020-10-02 2022-04-07 The Trustees Of Dartmouth College Method and agent for treating/preventing neurodegenerative disease and associated neuroinflammation and for evaluating putative prophylactics/therapeutics for treating/preventing neurodegenerative disease and neuroinflammation
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
JP2025519164A (ja) * 2022-05-27 2025-06-24 ジンキュア・コーポレイション 新規なペプチド及びその用途
EP4616868A1 (en) * 2022-11-09 2025-09-17 Ningbo Combireg Pharmaceutical Technology Co., Ltd Pharmaceutical composition of rip2 inhibitor in combination with immune checkpoint inhibitor and use thereof
CN116617224A (zh) * 2023-05-04 2023-08-22 上海交通大学医学院附属瑞金医院 OPN和p38 MAPK信号通路靶向调控剂在制备神经退行性疾病药物中的应用
CN118304388B (zh) * 2024-04-03 2025-02-11 南通大学 Tak1在制备治疗周围神经损伤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005726A1 (en) * 2010-03-08 2013-01-03 Derek Abbott Compositions and methods for treating inflammatory disorders
WO2012021647A2 (en) * 2010-08-10 2012-02-16 Sanford-Burnham Medical Research Institute Modulators of nod1 and nod2 signaling, methods of identifying modulators of nod1 and nod2 signaling, and uses thereof
WO2012026712A2 (ko) * 2010-08-23 2012-03-01 주식회사 강스템홀딩스 Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
MX340536B (es) * 2011-07-06 2016-07-13 Sykehuset Sorlandet Hf Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
WO2014066894A1 (en) * 2012-10-26 2014-05-01 Case Western Reserve University Biomarkers for nod2 and/or rip2 activity related application
EP3092496B1 (en) * 2014-01-11 2020-05-06 The J. David Gladstone Institutes In vitro assays for inhibition of microglial activation
US10336707B2 (en) * 2014-12-16 2019-07-02 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
KR20160129609A (ko) * 2015-04-30 2016-11-09 삼성전자주식회사 Ｂｒａｆ 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2021535152A5 (https=)
Nguyen et al. Nanotechnology-based drug delivery for central nervous system disorders
US11221329B2 (en) Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
JP2014517050A5 (https=)
EA201991078A1 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
NZ601547A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US11439624B2 (en) Promoting sleep using AT1 receptor blockers
JOP20210019A1 (ar) شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل
Ivgy-May et al. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial
Ortega et al. Indications of dexmedetomidine in the current sedoanalgesia trends in the critical patient
JPWO2020047414A5 (https=)
JP2019530711A5 (https=)
JP2012502105A5 (https=)
CN120478323A (zh) 丙磺舒在治疗癫痫性疾病、病症或病况中的用途
CN111135304A (zh) 治疗慢性、顽固性或原发性失眠症的联合用药物及其应用
JP6587299B2 (ja) 抗てんかん薬
JP6734469B2 (ja) ヒスタミン−３受容体インバースアゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種組合せ
JP6734470B2 (ja) ヒスタミン−３受容体インバースアゴニストとアセチルコリンエステラーゼ阻害剤との組合せ
Di Fabio et al. Hydroxyzine hydrochloride in familial restless legs syndrome
Chue Gabapentin treatment for premature ejaculation
Litvan Cholinergic approaches to the treatment of progressive supranuclear palsy
Park et al. Insomnia in Parkinson’s disease
WO2025006917A1 (en) Uses of iron chelators for treating stuttering
TW202535409A (zh) 用於治療神經退化性病症之組合物及方法
Kiryachkov et al. A Randomized Controlled Study of the Effectiveness of Electrophysiological Monitoring of Dexmedetomidine in Patients with Brain Damage of Various Origins